Clinical Trials Actively Recruiting Patients With Gynecologic Cancers


Get Permission

The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on gynecologic cancers—ovarian, cervical, and endometrial malignancies. These studies are researching stem cell therapy; antiretroviral combination therapy; XPO1 antagonists; anti–programmed cell death protein 1 (PD)-1 targeted treatments; stereotactic body radiation; and tyrosine kinase inhibitors.

All of the studies are listed on the National Institutes of Health website at ClinicalTrials.gov.

Phase I

Study Title: Phase I Study to Determine the Effects of Mesenchymal Stem Cells Secreting Interferon Beta in Patients With Advanced Ovarian Cancer

Study Type: Phase I/interventional/single-group assignment

Study Sponsor and Collaborators: MD Anderson Cancer Center

Purpose: To find the highest tolerable dose of human mesenchymal stem cells with interferon beta (MSC-INFβ) that can be given to patients with ovarian cancer and to test the safety of
MSC-INFβ

Primary Outcome Measures: Maximum tolerated dose of MSC-IFNβ; correlation between the number of MSC-IFNβ infused and the production of interferon-β and the number of MSC-IFNβ detected at the tumor sites via tumor biopsy pre- and post-treatment [time frame: 5 weeks]

Principal Investigator: Amanda L. Olson, MD, MD Anderson Cancer Center; (713) 792-8750

ClinicalTrials.gov Identifier: NCT02530047

***

Study Title: A Phase I Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II–IVA)

Study Type: Phase I/interventional/single-group assignment

Study Sponsor and Collaborators: Abramson Cancer Center of the University of Pennsylvania

Purpose: To determine the benefit of twice daily oral nelfinavir and weekly intravenous (IV) cisplatin in combination as radiosensitizers with daily whole-pelvic external-beam and intracavitary radiation brachytherapy in clinical stages IIA, IIB, IIIA, IIIB, and IVA cervical carcinoma limited to the pelvis

Primary Outcome Measures:
Number of adverse events [time 
frame: 2 years]

Principal Investigator: Fiona Simpkins, MD, Abramson Cancer Center; (855) 216-0098, penncancertrials@emergingmed.com

ClinicalTrials.gov Identifier: NCT02363829

***

Study Title: A Phase I Open-Label Study of the Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancer

Study Type: Phase I/interventional/parallel assignment

Study Sponsor and Collaborators: Memorial Sloan Kettering Cancer Center

Purpose: To test the safety of the investigational drug selinexor (KPT-330) in combination with carboplatin and paclitaxel chemotherapy in advanced ovarian or endometrial cancer

Primary Outcome Measures: Maximum tolerated dose [time frame: 1 year]

Principal Investigator: Vicky Makker, MD, Memorial Sloan Kettering Cancer Center; (646) 888-4224

ClinicalTrials.gov Identifier: NCT02269293

Phase II

Study Title: Phase II Open-Label Nonrandomized Trial of the Anti–PD-1 Therapy Pembrolizumab With First-Line Platinum-Based Chemotherapy Followed by 12 Months of Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer

Study Type: Phase II/interventional/single-group assignment

Study Sponsor and Collaborators: Medical College of Wisconsin

Purpose: To assess the progression-free survival in suboptimally cytoreduced epithelial ovarian/primary peritoneal/fallopian tube cancer treated with the novel combination of carboplatin every 21 days (triweekly)/weekly paclitaxel IV with pembrolizumab IV followed by maintenance pembrolizumab IV

Primary Outcome Measures: Progression-free survival of combination platinum-based therapy with anti–PD-1 therapy followed by maintenance anti–PD-1 therapy in patients with epithelial ovarian cancer [time frame: 24–48 months]

Principal Investigator: Denise Uyar, MD, Medical College of Wisconsin; (414) 805-6634, duyar@mcw.edu

ClinicalTrials.gov Identifier: NCT02766582

***

Study Title: A Phase II Study for Stereotactic Body Radiation Therapy for Definitive Treatment of Locally Advanced Cervical Cancer

Study Type: Phase II/interventional/single-group assignment

Study Sponsor and Collaborators: University of Texas Southwestern
Medical Center

Purpose: To determine whether stereotactic body radiation boost therapy is effective in women with locally advanced cervical cancer without an increased risk of acute gastrointestinal or genitourinary toxicity

Primary Outcome Measures: Primary tumor local control [time frame: 2 years]

Principal Investigator: Kevin ­Albuquerque, MD, University of Texas Southwestern Medical Center; (214) 645-8525

ClinicalTrials.gov Identifier: NCT02045433

***

Study Title: A Phase II Study of Cabozantinib (XL184) in Recurrent or Metastatic Endometrial Cancer

Study Type: Phase II/interventional/single-group assignment

Study Sponsor and Collaborators: National Cancer Institute

Purpose: To study how well cabozantinib-s-malate works in treating patients with recurrent or metastatic endometrial cancer

Primary Outcome Measures: Progression-free survival [time frame: from start of treatment to time of disease progression or death, assessed at 12 weeks]; response rate using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [time frame: up to 12 weeks posttreatment]

Principal Investigator: Neesha Dhani, MD, FRCPC, University Health Network–Princess Margaret Hospital; visit clinicaltrials.gov to see all recruiting locations and individual contact information

ClinicalTrials.gov Identifier: NCT01935934 ■

Editor’s Note: The clinical trials presented here do not represent all the trials listed on ClinicalTrials.gov. For the complete list, go to ClinicalTrials.gov.



Advertisement

Advertisement



Advertisement